The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The U.S. Food and Drug Administration said on Friday it has approved Boehringer Ingelheim's drug for patients with a type of ...

Cervical cancer is highly preventable with routine screening. To provide people with a cervix a comfortable and private ...

This article was featured in One Great Story, New York ’s reading recommendation newsletter. Sign up here to get it nightly.

Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance The agency’s top regulator of cell and gene therapies is taking a tougher approach on new drug approvals ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Eastman Kodak Co. reported a second-quarter loss and a year-over-year drop in sales, as the company leans on a Rochester ...

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval ...

Specifically, FDA has approved gardenia (genipin) blue for use in sports drinks, flavored or enhanced non-carbonated water, fruit drinks and ades, ready-to-drink teas, hard candy, and soft candy.

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

The Food and Drug Administration won’t sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won’t cause ...